



Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Docket No: AM1011163  
Patent

### INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement accompanies the new patent application submitted herewith of the following Inventors: Diane Harris BOSCHELLI; Nan ZHANG; Ana Carolina BARRIOS SOSA ; Haris DURUTLIC; Biqi WU

For: Thieno[3,2-b]Pyridine-6-Carbonitriles and Thieno[2,3-b]Pyridine-5-Carbonitriles as Protein Kinase Inhibitors.

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

2. ☐ Previously Cited Information

No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120. Prior application is Application Number \_\_\_\_\_ filed on \_\_\_\_\_ of \_\_\_\_\_ for \_\_\_\_\_


#### **CERTIFICATE OF MAILING 37 CFR §1.10**

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EU238171040US addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

November 21, 2003  
Date

Janice A. White  
Janice A. White

3. ☒ Newly Cited Information  
A legible copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed, except that no copy of a pending U.S. application, a U.S. patent, or a U.S. patent application publication is enclosed.
4. ☐ Concise Explanation  
Documents cited above which are not in the English Language  
a. ☐ have been explained in the specification.  
b. ☐ have an abstract (or other concise explanation) in English enclosed or, if readily available, a translation into English of the document is enclosed.
5. Form PTO-1449 is enclosed in duplicate.
6. Customer Number 25291.



---

Joy S. Goudie  
Attorney for Applicants  
Reg. No. 48,146

Wyeth  
Patent Law Department  
Five Giralda Farms  
Madison, NJ 07940  
Tel. No. (845) 602-2126

Substitution for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	TO BE ASSIGNED	
			Filing Date		
			First Named Inventor	Diane Harris Boschelli	
			Group Art Unit	N/A	
Examiner Name	N/A				
Attorney Docket Number	AM101163				
Sheet	1	of	4		

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US2002/00045 11 A1		Luzzio et al.	01-10-2002	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	2.	WO	03/013540 A1		Novartis AG	02-20-2003		<input type="checkbox"/>
	3.	WO	01/94353 A1		Pfizer Products Inc.	12-13-2001		<input type="checkbox"/>
	4.	WO	00/56738		Astrazeneca AB	09-28-2000		<input type="checkbox"/>
	5.	WO	99/24440		Pfizer Products Inc.	05-20-1999		<input type="checkbox"/>
	6.	EP	0 126 970 A2		Beecham Group PLC	04-24-1984		<input type="checkbox"/>

### OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	7.	AVIZIENYTE, Egle et al., "Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling" Nature Cell Biology, 07-22-2002, published online,	<input type="checkbox"/>
	8.	BLUME-JENSEN, Peter et al, "Oncogenic Kinase signalling", Nature (May 17, 2001) Vol. 411:355-365, Macmillan Magazines Ltd.	<input checked="" type="checkbox"/>
	9.	BOYCE, Brendan F. et al, "Requirement of pp60c-src Expression for Osteoclasts to Form Ruffled Borders and Resorb Bone in Mice", The American Society for Clinical Investigation, Inc. 10/1992, 1622-1627, Vol. 90 ISSN 0021-9738	<input type="checkbox"/>
	10.	BRIDGES, Aj et al, " Current progress towards the development of tyrosine kinase inhibitors as anticancer agents", Emerging Drugs (1998) Vol. 3: 279-292, ISSN 1361-9195, Ashley Publications Ltd.	<input type="checkbox"/>
	11.	CAMPBELL, Sharon L. et al, "Increasing complexity of Ras signaling", Oncogene (1998) Vol. 17: 1395-1413, ISSN 0950-9232/98, Stockton Press	<input type="checkbox"/>
	12.	DAVIES, Donna E. et al, " Targeting the Epidermal Growth Factor Receptor for Therapy of Carcinomas", Biochemical Pharmacology, (1996) Vol. 51: 1101-1110, ISSN 0003-2952/96, Elsevier Science Inc.	<input type="checkbox"/>
	13.	DU, Jing et al, " abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD", The American Physiological Society (1995) C487-C495, ISSN 0363-6143/95	<input type="checkbox"/>
	14.	ELICEIRI, Brian P. et al, "Selective Requirement for Src Kinases during VEGF-Induced Angiogenesis and Vascular Permeability", Molecular Cell, (December 1999) Vol. 4: 915-924, Cell Press	<input type="checkbox"/>
	15.	ELLIOTT, Richard L. et al, "The Preparation of 2-(Heterocyclyl) Thieno[3,2-b] Pyridine Derivatives", Tetrahedron (1987) Vol. 43, No. 14 3295-3302, ISSN 0040-4020/87 Pergamon Journals Ltd., Great Britain	<input type="checkbox"/>
	16.	ELLIS, Lee M. et al, "Down-regulation of Vascular Endothelial Growth Factor in a Human Colon Carcinoma Cell Line Transfected with an Antisense Expression Vector Specific for c-src", The Journal of Biological Chemistry, (1998) Vol. 273 No.2 1052-1057, The American Society for Biochemistry and Molecular Biology, Inc.	<input type="checkbox"/>
	17.	FOLKMAN, Judah et al, "Angiogenesis in cancer, Vascular, Rheumatoid and other disease", Nature Medicine (1995), Vol. 1, No. 1: 27-31	<input type="checkbox"/>
	18.	GARRETT, Michelle D. et al, "CDK inhibition and cancer therapy", Genetics & Development (1999) Vol. 9:104-111, ISSN 0959-437X, Elsevier Science Ltd.	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Substitute for form 1449/PTO			<b>Complete if Known</b>		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	TO BE ASSIGNED	
			Filing Date		
			First Named Inventor	Diane Harris Boschelli	
			Group Art Unit	N/A	
			Examiner Name	N/A	
Sheet	2	of	4	Attorney Docket Number	AM101163

### OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	19.	GATTONE II, Vincent H. et al, " Epidermal Growth Factor Ameliorates Autosomal Recessive Polycystic Kidney Disease in Mice", Developmental Biology (1995) Vol. 169: 504-510, ISSN 0012-1606/95, Academic Press, Inc.	<input type="checkbox"/>
	20.	GLAZER, Robert I. et al, "The Protein Kinase ABCs of Signal Transduction as Targets for Drug Development", Current Pharmaceutical Design, (1998) Vol. 4: 277-290, ISSN 1381-6182/98, Bentham science Publishers B.V.	<input type="checkbox"/>
	21.	GULLICK, W J et al, "Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers", British Medical Bulletin (1991) Vol. 47, No. 1, 87-98, The British Council	<input type="checkbox"/>
	22.	GUO, Wei et al, "Tyrosine Phosphorylation of the NR2B Subunit of the NMDA Receptor in the Spinal Cord during the Development and Maintenance of Inflammatory Hyperalgesia", The Journal of Neuroscience, (July 15, 2002) Vol.22, No.14: 6208-6217, ISSN 0270-6474/02/226208, Society for Neuroscience	<input type="checkbox"/>
	23.	HE, Zuwen et al, "The Human Cytomegalovirus UL97 Protein Is a Protein Kinase That autophosphorylates on Serines and Threonines" Journal of Virology, (Jan. 1997) Vol. 71, No.1: 405-411, ISSN 0022-538X/97, American Society for Microbiology	<input type="checkbox"/>
	24.	KAMENS, Joanne S. et al, " Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection", Investigation Drugs (2001) Vol.2,No.9:1213-1219, ISSN 1472-4472, PharmaPress Ltd.	<input type="checkbox"/>
	25.	KHAN, Misbahul Ain et al, " Thieno[2,3-b] pyridines and Thieno[3,2-b] pyridines by the Method of Gould-Jacobs", J. Heterocyclic Chem., (Aug. 1977) Vol. 14: 807-812	<input type="checkbox"/>
	26.	LOOMIS, William F. et al, "Histidine Kinases in signal transduction pathways of eukaryotes", Journal of Cell Science (1997) Vol. 110: 1141-1145, The Company of Biologists Ltd., Great Britain	<input type="checkbox"/>
	27.	MATTSSON, Erney et al, "Current Concepts in Restenosis Following Balloon Angioplasty", Trends in Cardiovascular Medicine, (1995) Vol.5, No.5:200-204, ISSN 1050-1738/95, Elsevier Science Inc.	<input type="checkbox"/>
	28.	MODJTAHEDI, Helmout et al, "The receptor for EGF and its ligands: Expression, prognostic value and target for thereapy in cancer", International Journal of Oncology, (1994) Vol. 4: 277-296,	<input type="checkbox"/>
	29.	MACIAS, Amparo et al, "Prognostic Significance of the receptor for Epidermal Growth Factor in Human Mammary Carcinomas", Anticancer Research (1987) Vol. 7: 459-464	<input type="checkbox"/>
	30.	NAM, Jeong-seok et al, "Src Family Kinase Inhibitor PP2 Restores the E-Cadherin/Catenin Cell Adhesion System in Human Cancer Cells and Reduces Cancer Metastasis", Clinical Cancer Research, (July 2002) Vol. 8: 2430-2436	<input type="checkbox"/>
	31.	MISSBACH, M. et al, " A Novel Inhibitor of the Tyrosine kinase Src Suppresses Phosphorylation of Its Major Cellur Substrates and reduces Bone Resorption in Vitro and in rodent Models In Vivo", Bone (May 1999), Vol.24, No.5: 437-449, ISSN 2786-3282/99, Elsevier Science Inc.	<input type="checkbox"/>
	32.	MYERS, Michael R. et al, "Inhibitors of Tyrosine Kinases Involved in Inflammation and Autoimmune", Current Pharmaceutical Design (1997) Vol. 3: 473-502, Bentham Science Publishers B.V.	<input type="checkbox"/>
	33.	NAUTA, Jeroen et al, "Biliary Epithelial Cells from Mice with Congenital Polycystic Kidney Disease Are Hyperresponsive to Epidermal Growth Factor", Pediatric Research (1995) Vol. 37, No.6: 755-763, ISSN 0031-3998/95/3706-0755 International Pediatric Research Foundation, Inc., U.S.A.	<input type="checkbox"/>
	34.	NISTER, Monica et al, Differential Expression of Platelet-derived Growth Factor Receptors in Human Malignant Glioma Cell Lines", The Journal of Biological Chemistry, (September 5, 1991) Vol.266, No. 25:16755-16763, The American Society for Biochemistry and Molecular Biology, Inc. U.S.A.	<input type="checkbox"/>
	35.	O'REILLY, Michael S. et al, "Endostatin: An Endogenous Inhyibitor of Angiogenesis and Tumor Growth" Cell, (January 24, 1997) Vol. 88: 277-285, Cell Press	<input type="checkbox"/>
	36.	O'REILLY, Michael S. et al, "Angiostatin induces and sustains dormancy of human primary tumors in mice", Nature Medicine (June 1996), Vol. 2, No.6:689-692	<input type="checkbox"/>
	37.	O'REILLY, Michael S. et al, "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma", Cell (October 21, 1994) Vol. 79: 315-328, Cell Press	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Substitute for form 1449/PTO			<b>Complete if Known</b>		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	TO BE ASSIGNED	
(use as many sheets as necessary)			Filing Date		
			First Named Inventor	Diane Harris Boschelli	
			Group Art Unit	N/A	
			Examiner Name	N/A	
Sheet	3	of	4	Attorney Docket Number	AM101163

### OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	38.	PAUL, Robert et al, "Src deficiency or blockade of Src activity in Mice provides crebral protection following stroke", Nature Medice (February 2001), Vol. 7, No. 2: 222-227, Nature Publishing Group	<input type="checkbox"/>
	39.	RAINES, Elaine W. et al, "Mutiple growth factors are associated with lesions of atherosclerosis: specificity or redundancy", BioEssays (1996) Vol. 18, No.4: 271-282, ICSU Press	<input type="checkbox"/>
	40.	REISS, Michael et al, "Activation of the Autocrine Transforming Growth Factor & Pathway in Human Squamous Carcinoma Cells", Cancer Research (December 1, 1991) Vol. 51: 6254-6262	<input type="checkbox"/>
	41.	REUTERS, "Novel approach to treatment of stroke shows promise in mice", Nature Medicine (February 6, 2001), Vol. 7: 222-228	<input type="checkbox"/>
	42.	REUTERS, "Learning More About How Cancer Spreads", The New York Times (2002)	<input type="checkbox"/>
	43.	RUSCH, Valerie et al, "The Epidermal Growth Factor Receptor and its Ligands as Therapeutic Targets in Human Tumors", Cytokine & Growth Factor reviews (1996) Vol. 7, No. 2:133-141, ISSN 1359-6101/96, Elsevier Science Ltd., Great Britain	<input type="checkbox"/>
	44.	SATO, Thomas N. et al, "Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation", Nature (July 6, 1995), Vol. 376: 70-74	<input type="checkbox"/>
	45.	SAVAGE, David G. MD et al, "Imatinib Mesylate - A New Oral Targeted Therapy", The New England Journal of Medicine (February 28, 2002) Vol. 346, No. 6: 683-693, Massachusetts Medical Society	<input type="checkbox"/>
	46.	SAWYER Tomi et al, "Src inhibitors: genomics to therapeutics", Expert Opinion Investigative Drugs (2001) Vol. 10 No.7:1327-1344, ISSN 1354-3784, Ashley Publications Ltd.	<input type="checkbox"/>
	47.	SCHWARTZBERG, Pamela L. et al, "The many faces of Src: multiple functions of a prototypical tyrosine kinase", Oncogene (1998) Vol. 17: 1463-1468, ISSN 0950-9232/98, Stockton Press	<input type="checkbox"/>
	48.	SEGER, Rony et al, "The MAPK signaling cascade", FASEB Journal (1995) Vol. 9: 726-735, ISSN 0892-6638/95/0009-0726, FASEB	<input type="checkbox"/>
	49.	SHAWVER, Laura K. et al, "Receptor tyrosine kinases as targets for inhibition of angiogenesis", Drug Discovery Today (February 2, 1997) Vol. 2, No. 2:50-63, ISSN 1359-6446/97, Elsevier Science Ltd.	<input type="checkbox"/>
	50.	SILVARAMAN, Vimala et al, " Hyperexpression of Mitogen-activated Protein Kinase in Human Breast Cancer", J. Clinical Investigation (April 1997) Vol. 99, No.7: 1479-1483, ISSN 0021-9738/97/04/1478/06, The American Society for Clinical Investigation, Inc.	<input type="checkbox"/>
	51.	SLAMON, Dennis J. et al, "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene", Science, (January 9, 1987), Vol. 235: 177-182	<input type="checkbox"/>
	52.	SLAMON, Dennis J. et al, "Studies of the HER-2/neu Proto-Oncogene in Human Breast and Ovarian Cancer", Science (May 12, 1989), Vol.244: 707-712	<input type="checkbox"/>
	53.	SORIANO, Philippe et al, "Targeted Disruption of the c-src Proto-Oncogene Leads to Osteopetrosis in Mice", Cell (February 22, 1991), Vol. 64: 693-702, Cell Press	<input type="checkbox"/>
	54.	STALEY, Charles A. et al, "Decreased Tumorigenicity of a Human Colon Adenocarcinoma Cell Line by an Antisense Expression Vector Specific for c-Src", Cell Growth & Differentiation (March 1997) Vol. 8: 269-274	<input type="checkbox"/>
	55.	STRAWN, Laurie M. et al, "Inhibition of Glioma Cell Growth by a Truncated Platelet-derived Growth Factor-B Receptor", The Journal Of Biological Chemistry (August 19, 1994) Vol.269, No. 33: 21215-21222, The American Society for Biochemistry and Molecular Biology, Inc, U.S.A.	<input type="checkbox"/>
	56.	TRAXLER, Peter et al, "Tyrosine kinase inhibitors in cancer treatment (Part II)", Expert Opinion Ther. Patents (1998), Vol. 8 No. 12:1599-1625 , ISSN 1354-3776, Ashley Publications Ltd.	<input type="checkbox"/>
	57.	URBAN, L. et al, "Chronic Neuropathic Pain: Pathomechanism and Pharmacology", Drug Development Research (2002) Vol. 54:159-166, Wiley-Liss, Inc.	<input type="checkbox"/>
	58.	WAEGELL, W. et al, "A420983., a Novel, Small Molecule Inhibitor of LCK Prevents Allograft Rejection", Transplantation Proceedings (2002) Vol.34:1411-1417, ISSN 0041-1345/02, Elsevier Science Inc.	<input type="checkbox"/>
	59.	WEBSTER, Kevin R. et al, "The therapeutic potential of targeting the cell cycle", Expert Opinion Invest. Drugs (1998), Vol.7 No.6:865-887, ISSN 1354-3784, Ashley Publications Ltd.	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Application Number		TO BE ASSIGNED	
		Filing Date			
		First Named Inventor		Diane Harris Boschelli	
		Group Art Unit		N/A	
		Examiner Name		N/A	
Sheet	4	of	4	Attorney Docket Number	AM101163

<b>OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No.	<small>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the            item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s),            publisher, city and/or country where published.</small>	T
	60.	WILSON, Patricia D. et al, "Autocrine, endocrine and paracrine regulation of growth abnormalities in autosomal dominant polycystic kidney disease", European Journal of Cell Biology (1993), Vol. 61:131-138, Wissenschaftliche Verlagsgesellschaft mbH	<input type="checkbox"/>
	61.	WOLF, D.G. et al, "Characterization of the human cytomegalovirus UL97 gene product as a virion-associated protein kinase", Archives of Virology (1998) Vol. 143:1223-1232, Springer-Verlag, Austria	<input type="checkbox"/>
	62.	YU, Xian-min et al, "Src, a molecular switch governing gain control of synaptic transmission mediated by N-methyl-D-aspartate receptors", Proc. National Academy of Sciences (July 1999), Vol. 96:7697-7704, U.S.A.	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.